Loading clinical trials...

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

NCT03004833•University of Cologne

Summary

The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically proven classical HL
•First diagnosis, no previous treatment
•Age: 18-60 years
•Stage I, IIA with risk factors a-d, IIB with RF c-d:
•1. large mediastinal mass
•2. extranodal lesions
•3. elevated ESR
•4. ≥ 3 nodal areas confirmed by central review.

Exclusion Criteria

•Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)
•History of other malignancy ≤ 5 years
•Prior chemotherapy or radiation therapy
•Concurrent disease precluding protocol treatment
•Pregnancy, lactation
•Non-compliance

Locations (1)

University Hospital of Cologne

Cologne, Germany

Key Dates

Start Date

February 21, 2017

Primary Completion Date

August 22, 2022

Completion Date

August 22, 2022

Last Updated

April 3, 2025

Enrollment

110

ACTUAL participants

Conditions

Classical Hodgkin Lymphoma

Interventions

Nivolumab

DRUG

Adriamycin

DRUG

Vinblastine

DRUG

Dacarbazine

DRUG

European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

NCT07356882

Classical Hodgkin Lymphoma

View study

RECRUITINGPHASE1

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT05362773

Leukemia, Acute MyeloidMyelodysplastic Syndromes+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Inclusion Criteria

Exclusion Criteria

European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Itacitinib + Everolimus in Hodgkin Lymphoma

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy